• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

FDA Panel Unanimously Approves Alzheimer’s Treatment Leqembi


Decision based on data collected from patients in the early stages of the disease.

Purple day. Epilepsy awareness day Awareness Purple ribbon. Image Credit: Adobe Stock Images/vetre

Image Credit: Adobe Stock Images/vetre

Eisai, a pharmaceutical company, and Biogen, a biotechnology organization, have announced the FDA’s approval of Leqembi (lecanemab-irmb), for the treatment of Alzheimer’s disease. The injection is recommended for patients with mild cognitive impairment or mild dementia, the demographic in which clinical trials were introduced.

Reportedly, continued approval is contingent on verification of clinical benefit in a confirmatory trial.

Reference: FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease. June 9, 2023. Accessed June 13, 2023. https://www.globenewswire.com/news-release/2023/06/09/2685832/0/en/FDA-Advisory-Committee-Votes-Unanimously-to-Confirm-the-Clinical-Benefit-of-LEQEMBI-lecanemab-irmb-for-the-Treatment-of-Alzheimer-s-Disease.html

Related Videos
Related Content